Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Healios KK ( (JP:4593) ) just unveiled an update.
Healios K.K. has announced changes in its executive management team, effective March 27, 2025. Hardy TS Kagimoto remains Chairman and CEO, while Richard P. Kincaid takes on additional responsibilities as Executive Officer and CFO, overseeing business development, finance, and legal affairs. Hironobu Kimura will manage research, manufacturing, and human resources. The resignation of Masanori Sawada as Executive Vice President and CMO marks a significant shift in the company’s leadership structure, potentially impacting its strategic direction and operational focus.
More about Healios KK
Healios K.K. operates in the biotechnology industry, focusing on regenerative medicine and cell therapy. The company is known for its development of innovative treatments aimed at addressing unmet medical needs, particularly in the areas of ophthalmology and organ regeneration.
YTD Price Performance: 54.24%
Average Trading Volume: 3,688,727
Technical Sentiment Signal: Sell
Current Market Cap: Yen27.64B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.